Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Diseases of the Esophagus

Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma (Rice): Preliminary Results

View Full Paper
Ask AI
Bookmark
Share

Authors

LLLin LinHLHongxuan LiLZLei Zhao

Discussion

Loading...

Member takes

Overview

Phase 2 trial shows improved overall survival in patients receiving induction immunotherapy followed by concurrent chemoradiotherapy for esophageal squamous cell carcinoma.

Key Points

  • Induction immunotherapy combined with concurrent chemoradiotherapy improved overall survival rates in patients with unresectable esophageal cancer.
  • The 2-year overall survival was observed at 83.4%, demonstrating a significant survival benefit for participants receiving this treatment approach.
  • Safety evaluations indicated that notable adverse events included lymphopenia and esophagitis during treatment.
  • Longer follow-ups are required to confirm sustained survival benefits from the treatment regimen in this patient population.

Cite This Study

Lin et al. (2025) studied this question.

synapsesocial.com/papers/68c23cf6b210217d6478b906https://doi.org/10.1093/dote/doaf061.024
View Full Paper
Ask AI
Bookmark
Share